What Is DTP (Direct-to-Pocket) Pricing?
Direct-to-Pocket (DTP) pricing is a pharmaceutical channel model in which a manufacturer sets a fixed, transparent cash price for a drug that patients purchase directly — bypassing insurers, pharmacy benefit managers (PBMs), and retail pharmacy networks. The patient pays that price out of their own funds at the point of dispensing, with no insurance claim submitted and no PBM adjudication involved.
An important disambiguation: "DTP" also stands for Direct-to-Patient, a term focused on home-delivery logistics rather than cost structure. The two are frequently conflated because many manufacturer platforms bundle both — cash pricing and home delivery — into a single program. Direct-to-Pocket specifically describes the patient's payment experience and the absence of insurance processing, not the fulfillment method.
A practical example: a patient on a high-deductible health plan purchasing a GLP-1 medication through a manufacturer-run platform at a fixed monthly cash price. The price may be lower than the insurer-adjudicated retail rate — but because no claim is filed, the purchase does not count toward the patient's deductible.
How Direct-to-Pocket Pricing Works
The end-to-end flow typically follows five steps:
- Manufacturer sets a fixed cash price outside existing PBM contract structures, often below the published Wholesale Acquisition Cost (WAC).
- Patient accesses the drug through a manufacturer-owned or authorized platform, frequently integrated with a telehealth prescribing consult so that diagnosis, prescription, and dispensing occur in one digital experience.
- Prescription is fulfilled via direct home delivery, including temperature-controlled shipping where required for biologics or GLP-1 medications.
- Patient pays cash at the point of dispensing. No insurance claim is submitted, and no PBM adjudication occurs — meaning the insurer never sees the transaction.
- Because no claim is filed, the purchase does not accumulate toward the patient's deductible or out-of-pocket maximum under their health plan.
This last point is consequential for patient financial planning and is one of the least understood aspects of DTP programs. Some employers and PBMs are beginning to explore hybrid arrangements that attempt to address the deductible gap, though these models are still evolving.
Direct-to-Pocket vs. Direct-to-Patient (DTP)
Both terms share the abbreviation "DTP" and are frequently used interchangeably, but they describe fundamentally different aspects of pharmaceutical distribution. Understanding the distinction matters for pricing teams, benefits designers, and supply-chain professionals who may be working on the same program from different angles.
| Dimension | Direct-to-Pocket | Direct-to-Patient |
|---|---|---|
| Primary focus | Cost structure and cash pricing | Fulfillment logistics and home delivery |
| Who uses the term | Pricing, benefits, and payer teams | Pharma ops and supply-chain teams |
| Deductible impact | Explicitly none; cash payment is outside adjudication | Not the primary concern of the term |
| Typical context | Manufacturer cash-pay platforms, high-deductible patients | Clinical trial supply, specialty home delivery |
Use "Direct-to-Pocket" when discussing patient cost structure and cash-pay pricing strategy; use "Direct-to-Patient" when discussing drug fulfillment, home-delivery logistics, or supply-chain operations.
Direct-to-Pocket Pricing in Pharmaceutical and Enterprise Contexts
DTP pricing surfaces across three main contexts for manufacturer pricing teams and employer benefit designers.
Manufacturer-direct cash-pay platforms are the most visible application. Several large pharmaceutical companies have launched dedicated programs that allow patients to purchase branded medications at fixed cash prices directly through manufacturer-controlled channels. These platforms often combine telehealth prescribing and pharmacy fulfillment in a single experience.
Employer-sponsored or direct-to-employee (DTE) arrangements extend the model to self-insured employers. Rather than reaching individual patients, the manufacturer contracts with an employer, who then makes the fixed-price drug available as a benefit. This structure can reduce pharmacy spend for the employer while maintaining predictable pricing for the manufacturer.
Telehealth-integrated DTP is particularly common for GLP-1 medications and mental-health drugs, where prescribing and dispensing are bundled on a single platform, reducing friction for the patient.
Multi-channel manufacturers must manage DTP cash prices alongside WAC and PBM-contracted rates simultaneously — a dynamic that creates channel-conflict and price-governance considerations that require careful coordination.
Limitations and Strategic Risks
Deductible non-accumulation is the most consequential limitation. Because no insurance claim is filed, cash-pay purchases do not count toward the patient's annual deductible or out-of-pocket maximum. Patients who later need other covered services may find they have made little progress toward their cost-sharing thresholds, which can cause dissatisfaction with the program.
Affordability ceiling. Even a below-WAC cash price may remain unaffordable for lower-income patients compared with Medicaid coverage or a fully insured plan with a low copay. DTP programs are generally better suited to patients with moderate-to-high incomes and high-deductible plans than to the broadest patient population.
Channel conflict. DTP programs can create tension with existing PBM contracts and pharmacy network agreements if cash prices are not governed consistently across channels. A manufacturer offering a significantly lower direct cash price than the PBM-contracted price may face renegotiation pressure or formulary consequences.
Payer response risk. Some payers have adjusted formulary status or coverage policies in response to manufacturer DTP initiatives, effectively pushing back on programs they perceive as circumventing their role in drug pricing and utilization management.
Related Terms: Direct-to-Patient (DTP) | Out-of-Pocket Pricing | Cash-Pay Pricing | Direct-to-Consumer (DTC)
